Ectoin, Explained: What a 7% Cream Did in Barrier-Impaired Skin Studies, and Who Paid for the Review That Pooled Them
Ectoin appears on K-beauty and European ingredient lists as a "bacteria-derived hydrator," usually with no percentage. The clinical work behind it is narrower than that suggests: most tested one 7% cream in eczema or isotretinoin-dried skin, and the main summary was written by that cream's manufacturer.
What ectoin is
Ectoin is a small cyclic amino acid that salt-loving microbes make to survive drying. Galinski, Pfeiffer and Trüper reported it in 1985 from Ectothiorhodospira halochloris, hence the name. It is a "compatible solute" cells can stockpile safely.
How it is made
Industrial supply comes from Halomonas elongata through "bacterial milking": cells grown in high salt build up ectoin, then a drop to low salt makes them release it for filtering.
The proposed mechanism
The review below describes a "water shell" around proteins and membranes that stabilizes them against dryness. That echoes the water-replacement idea in the trehalose article. In both cases the mechanism rests mostly on lab and animal work, so it explains why it was tried, not what a cream does.
The review everyone cites
Kauth and Trusova (Dermatology and Therapy, 2022) screened 230 records through October 2021 and kept six clinical studies, five in atopic dermatitis and one on isotretinoin dryness. The creams held 5.5% to 7.0% ectoin. The authors called the studies heterogeneous and some underpowered.
What the studies measured
Marini and colleagues used 7% ectoin cream twice daily for four weeks in 65 adults, against a non-steroidal comparator cream on the same person. Objective SCORAD fell from 7.5 to 3.8, non-inferior, with no vehicle-only arm. In the Hon study, TEWL improved (p = 0.035) but hydration did not.
The isotretinoin comparison
In 44 isotretinoin patients, 7% ectoin cream was compared with dexpanthenol cream. In month one, hydration rose 15.1% versus 7.3%, and TEWL fell 23.9% versus 18.2%. The review notes the paper reported no test of that gap. For the comparator, see the panthenol article.
Who paid
First author Marion Kauth is an employee of bitop AG, which makes the ectoin in these creams, and the company paid the journal's publication fee. That does not make the findings wrong, but it is why they read as preliminary. Seven of 455 participants dropped out over side effects.
What it means for a face cream
Labels list "ectoin" without a concentration, and no study tested the lower levels a serum might use. The 7% data came from creams on eczema-affected or retinoid-dried skin. For a humectant with documented ranges, glycerin has more numbers.
This article summarizes published research and is not medical advice. Patch test any new product first, and see a dermatologist about eczema, retinoid-related dryness or any skin concern.
All content is fact-checked under our editorial standards.